GlassScriptPhysician profile
Jon Michael Berry
NPI 1124085469
$9,040.04
in general payments reported to CMS, 2019-2025
21 companies · $460 in 2025
The $460 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,605 · 2020: $153 · 2021: $57.06 · 2022: $1,211 · 2023: $427 · 2024: $126 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $996 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $995.89 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,540.53 | 2019-2020 | |
| Zimmer Biomet Holdings, INC. | $1,210.87 | 2022 | |
| Davol INC. | $521.18 | 2023-2025 | Phasix Mesh |
| Medtronic, INC. | $143.73 | 2024-2025 | Endoflip, Ligasure |
| Becton, Dickinson and Company | $104.57 | 2025 | Phasix Mesh |
| Ethicon US, LLC | $72.23 | 2019-2021 | |
| Acell, INC. | $53.59 | 2019 | |
| Kls-Martin L.P. | $52.60 | 2025 | |
| Kci USA, INC. | $43.94 | 2020-2023 | Prevena, V.A.C. Veraflo Cleanse Choice |
| Avanos Medical | $36.49 | 2024 | Peg, Entral |
| Pacira Pharmaceuticals Incorporated | $35.48 | 2019-2025 | Exparel |
| Solventum Corporation | $35.44 | 2024 | Prevena, V.A.C. Veraflo Cleanse Choice |
| Covidien LP | $35.21 | 2019 | |
| Merck Sharp & Dohme LLC | $30.93 | 2019-2024 | Bridion |
| Boston Scientific Corporation | $21.51 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heron Therapeutics, INC. | $20.10 | 2021 | |
| Csl Behring | $18.82 | 2019 | |
| Teleflex LLC | $18.00 | 2023 | Quikclot |
| La Jolla Pharmaceutical Company | $15.81 | 2024 | Xerava |
| Phathom Pharmaceuticals, INC. | $15.29 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $13.72 | 2023 | Gattex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Berry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.